Osteosarcoma

Osteosarcoma (OSA) is the most common primary malignant bone tumor in dogs and cats, characterized by the proliferation of malignant osteoblasts that produce osteoid or immature bone. It is an aggressive, locally invasive neoplasm with a high metastatic potential, most frequently affecting the appendicular skeleton of large and giant breed dogs. The tumor arises within the medullary cavity, destroys cortical bone, and extends into the periosteum and surrounding soft tissues. Histologically, OSA is classified into osteoblastic, chondroblastic, fibroblastic, and telangiectatic subtypes, with the osteoblastic form being most common. The disease is staged using the TNM system, with most dogs presenting with stage IIb (high-grade, extracompartmental) tumors. Surgical management, typically limb amputation or limb-sparing procedures, combined with adjuvant chemotherapy, remains the standard of care. The prognosis is guarded, with median survival times of approximately 1 year with treatment, and less than 4 months without therapy.

The exact etiology of osteosarcoma is multifactorial and not fully understood. Several risk factors have been identified, including genetic predisposition, rapid bone growth, and prior bone trauma. In dogs, certain breeds such as the Rottweiler, Greyhound, Great Dane, and Saint Bernard have a significantly higher incidence, suggesting a hereditary component. Molecular studies have implicated mutations in tumor suppressor genes (e.g., p53, Rb) and dysregulation of growth factor signaling pathways (e.g., IGF-1, TGF-β). Chronic inflammation, metallic implants, and previous radiation therapy have been reported as rare iatrogenic causes. In cats, OSA is less common and often associated with older age, with no clear breed predisposition. The role of viral oncogenesis has been hypothesized but not confirmed. Biomechanical stress on weight-bearing bones, particularly the metaphyseal regions of long bones, may contribute to the development of OSA, as these are common sites of tumor origin.

Osteosarcoma accounts for approximately 85% of all primary bone tumors in dogs and 70% in cats. It predominantly affects middle-aged to older animals, with a median age of 7-9 years in dogs and 8-10 years in cats. Large and giant breeds are at highest risk, with a male-to-female ratio of approximately 1.3:1. The appendicular skeleton is involved in 75% of canine cases, with the forelimb (radius, humerus) more commonly affected than the hindlimb (femur, tibia). The axial skeleton (skull, ribs, vertebrae) is less frequently involved. In cats, the hindlimbs are more commonly affected. Breed-specific incidence rates are highest in Rottweilers, Greyhounds, Great Danes, and Saint Bernards. The lifetime risk for Rottweilers is estimated at 5-10%. There is no significant sex predilection in cats. The disease is rare in small breed dogs and mixed breeds, suggesting a genetic basis.

Osteosarcoma arises from primitive mesenchymal cells that differentiate into osteoblasts. These malignant cells produce osteoid and immature bone, leading to a mixed lytic and proliferative radiographic pattern. The tumor grows rapidly within the medullary cavity, causing endosteal erosion and cortical destruction. As the tumor expands, it elevates the periosteum, stimulating a periosteal reaction that may appear as a sunburst or Codman's triangle on radiographs. The tumor invades adjacent soft tissues, causing pain, swelling, and pathological fractures. Micro-metastases to the lungs are present in over 90% of dogs at the time of diagnosis, even if not detectable on thoracic radiographs. The tumor also induces angiogenesis, osteoclast activation, and local inflammation, contributing to bone resorption and pain. Systemic effects include paraneoplastic syndromes such as hypercalcemia and leukocytosis. The high metastatic potential is due to hematogenous spread, with the lungs being the most common site of metastasis, followed by bone and other organs.

Intrinsic risk factors include breed, age, sex, and genetic predisposition. Large and giant breeds are at highest risk due to rapid bone growth and increased bone remodeling. Genetic mutations in tumor suppressor genes (p53, Rb) and oncogenes (c-myc, ras) have been identified. Extrinsic factors include trauma, which may act as a cofactor by inducing inflammation and cellular proliferation. Prior radiation therapy for other tumors has been associated with the development of OSA. Chronic osteomyelitis and metallic implants have been rarely implicated. Nutritional factors, such as high-calorie diets leading to rapid growth, may increase risk. Neutering before 1 year of age has been associated with an increased risk in some studies, possibly due to hormonal influences on bone growth. Environmental factors, such as exposure to chemicals or radiation, are not well-established.

The most common clinical sign is progressive, non-weight-bearing lameness that does not improve with rest or anti-inflammatory medications. The lameness is often insidious in onset and worsens over weeks to months. On physical examination, a firm, painful swelling may be palpable at the metaphyseal region of the affected bone. The swelling is often warm to the touch due to increased vascularity. Pathological fracture may occur, causing acute, severe lameness and crepitus. Systemic signs such as lethargy, anorexia, and weight loss may be present in advanced stages. In cases of pulmonary metastasis, coughing, dyspnea, and exercise intolerance may be observed. Neurological deficits may occur if the tumor involves the spine or if there is nerve compression. Paraneoplastic hypercalcemia can cause polyuria, polydipsia, and gastrointestinal signs. The lameness may be graded on a scale of 0-5, with most affected animals showing grade 3-4 lameness.

Differential diagnoses for osteosarcoma include: 1) Chondrosarcoma - a malignant cartilage-producing tumor that is slower to metastasize; radiographically, it often shows a more lytic pattern with less periosteal reaction. 2) Fibrosarcoma - a malignant fibroblastic tumor that is less common and has a better prognosis; histopathology is definitive. 3) Hemangiosarcoma - a highly aggressive vascular tumor that may involve bone; it is associated with rapid growth and early metastasis. 4) Fungal osteomyelitis (e.g., blastomycosis, coccidioidomycosis) - presents with lameness and bone lysis; radiographs may show a mixed pattern, but there is often a history of travel to endemic areas and systemic signs. 5) Bacterial osteomyelitis - usually associated with a penetrating wound or prior surgery; radiographs show periosteal reaction and sequestra. 6) Bone cyst - a benign lesion that may cause pathological fracture; radiographs show a well-defined lytic area. 7) Metastatic bone tumors - from primary tumors such as mammary carcinoma or prostatic carcinoma; multiple lesions may be present. 8) Multiple myeloma - a plasma cell tumor that can cause multiple lytic bone lesions and hypercalcemia. 9) Hypertrophic osteopathy - a periosteal reaction along the diaphysis of long bones, often associated with pulmonary masses. 10) Panosteitis - an inflammatory condition of young large-breed dogs causing shifting leg lameness; radiographs show medullary sclerosis.

The diagnostic workup for suspected osteosarcoma follows a systematic approach: 1) Complete history and physical examination, including orthopedic and neurological assessments. 2) Three-view thoracic radiographs to evaluate for pulmonary metastases. 3) Radiographs of the affected bone in two orthogonal views to assess the primary tumor. 4) Advanced imaging (CT or MRI) of the primary tumor to determine the extent of bone destruction and soft tissue involvement, and to aid in surgical planning. 5) Fine-needle aspiration of the bone lesion for cytology, which may show malignant osteoblasts, but is not always diagnostic. 6) Core needle biopsy or incisional biopsy for histopathological confirmation. The biopsy should be taken from the center of the lesion, avoiding areas of necrosis or fracture. 7) Complete blood count, serum biochemistry, and urinalysis to assess overall health and detect paraneoplastic syndromes. 8) Bone scintigraphy or whole-body CT to detect skip metastases or other bone lesions. 9) If biopsy is inconclusive, a second biopsy or intraoperative biopsy may be performed. 10) Staging based on the TNM system, with most dogs presenting as stage IIb.

Hematology may reveal a mild to moderate leukocytosis due to inflammation or paraneoplastic neutrophilia. Anemia may be present in chronic cases. Serum biochemistry may show elevated alkaline phosphatase (ALP), particularly the bone isoenzyme, which is a negative prognostic indicator. Hypercalcemia may occur in 10-20% of cases due to paraneoplastic secretion of parathyroid hormone-related protein. Other findings may include elevated lactate dehydrogenase and creatine kinase. Urinalysis is usually unremarkable. Coagulation panel (PT, aPTT, platelet count) is typically normal, but a thrombocytosis may be present. Inflammatory biomarkers such as C-reactive protein (CRP) and serum amyloid A (SAA) may be elevated. Synovial fluid analysis is not typically performed for bone tumors, but if the joint is involved, it may show a mononuclear inflammatory response. Histopathology of the biopsy is essential for diagnosis, showing malignant osteoblasts producing osteoid. Immunohistochemistry may be used to differentiate OSA from other sarcomas, with positive staining for vimentin and osteocalcin.

Radiography: The classic radiographic appearance of osteosarcoma is a mixed lytic and proliferative lesion in the metaphyseal region of a long bone. There is cortical destruction, periosteal reaction (sunburst, Codman's triangle), and soft tissue swelling. Pathological fracture may be present. Thoracic radiographs may reveal pulmonary metastases, which appear as well-defined nodules. Ultrasonography: Not typically used for primary bone tumors, but may be used to evaluate abdominal organs for metastasis. CT: Provides detailed assessment of bone destruction, soft tissue extension, and is essential for surgical planning. 3D reconstructions can help determine the extent of resection. MRI: Superior for evaluating soft tissue and bone marrow involvement, particularly in axial skeleton tumors. It is useful for surgical planning in limb-sparing procedures. Bone scintigraphy: Technetium-99m methylene diphosphonate scans can detect areas of increased bone turnover, including primary tumors and metastases. It is sensitive but not specific. Angiography/Fluoroscopy: May be used to assess vascular involvement in limb-sparing surgery. Arthroscopy: Not indicated for bone tumors, but may be used to evaluate joint involvement if there is concern.

Fine-needle aspiration of the bone lesion may yield malignant osteoblasts, which are pleomorphic, spindle-shaped cells with hyperchromatic nuclei and prominent nucleoli. However, cytology is often non-diagnostic due to the dense nature of the tumor. Core needle biopsy or incisional biopsy is the gold standard for diagnosis. Histopathology reveals malignant osteoblasts producing osteoid or immature bone. The tumor is classified into subtypes: osteoblastic (most common), chondroblastic, fibroblastic, and telangiectatic. The mitotic index is high, and there is evidence of vascular invasion. Surgical margins are evaluated for the presence of tumor cells. Special stains such as Masson's trichrome may help differentiate osteoid from collagen. Immunohistochemistry for vimentin, osteocalcin, and osteonectin can confirm the osteoblastic origin. The grade of the tumor (I-III) is based on mitotic count, nuclear pleomorphism, and necrosis, with most OSA being high-grade (II-III).

The standard of care for appendicular osteosarcoma is amputation of the affected limb followed by adjuvant chemotherapy. Amputation provides local control and alleviates pain. For dogs with pre-existing orthopedic or neurological conditions, limb-sparing surgery may be considered, which involves resection of the tumor and reconstruction with a bone graft or endoprosthesis. Limb-sparing is associated with higher complication rates, including infection, implant failure, and tumor recurrence. For axial skeleton tumors, surgical excision may be possible depending on the location. Radiation therapy can be used as a palliative treatment for pain relief, but it does not improve survival. Chemotherapy with carboplatin or cisplatin is recommended, with protocols including 4-6 cycles at 3-week intervals. Doxorubicin may be used alone or in combination. For cats, amputation is also the treatment of choice, and chemotherapy may be considered, but the benefit is less clear. Postoperative pain management includes opioids (e.g., morphine, hydromorphone) and NSAIDs (e.g., carprofen, meloxicam). Physical rehabilitation is important for recovery after amputation.

The prognosis for osteosarcoma is guarded. Without treatment, the median survival time is approximately 4 months. With amputation alone, the median survival time is 4-6 months. With amputation and adjuvant chemotherapy, the median survival time increases to 10-12 months, with 1-year survival rates of 40-50% and 2-year survival rates of 20-25%. Negative prognostic indicators include elevated serum alkaline phosphatase, high tumor grade, presence of metastasis at diagnosis, and telangiectatic subtype. Positive prognostic indicators include distal radial location, absence of metastasis, and complete surgical excision. In cats, the prognosis is slightly better, with median survival times of 1-2 years after amputation, with or without chemotherapy. Local recurrence after limb-sparing surgery is reported in 10-30% of cases. The quality of life after amputation is generally good, with most dogs adapting well to three-legged locomotion.

Postoperative follow-up is crucial for monitoring for metastasis and local recurrence. Thoracic radiographs should be repeated every 3 months for the first year, then every 6 months thereafter. Physical examinations should be performed at the same intervals. For limb-sparing patients, radiographs of the surgical site should be taken at 4, 8, and 12 weeks postoperatively to assess bone healing and implant stability. Suture removal is typically 10-14 days after surgery. Activity restriction is recommended for 6-8 weeks after amputation, with gradual increase in exercise. Physical therapy, including passive range of motion exercises and hydrotherapy, can aid in rehabilitation. Long-term monitoring for complications such as implant failure, infection, or tumor recurrence is essential. Blood work, including serum ALP, may be monitored as a tumor marker. Owners should be educated on signs of metastasis, such as coughing, lameness, or weight loss.

Pearls: 1) Always obtain thoracic radiographs before surgery to rule out pulmonary metastasis. 2) Biopsy should be performed by a surgeon who will perform the definitive surgery, and the biopsy tract should be excised en bloc. 3) In limb-sparing surgery, careful patient selection is critical; ideal candidates are those with distal radial tumors and no concurrent orthopedic disease. 4) Use of a cortical allograft in limb-sparing can provide structural support, but complications are common. 5) Amputation is well-tolerated in most dogs, even those with mild arthritis, but pre-operative assessment of the contralateral limb is essential. 6) Chemotherapy should be initiated as soon as possible after surgery, ideally within 2 weeks. Pitfalls: 1) Failure to recognize pathological fracture, which may complicate surgery. 2) Incomplete surgical margins due to inadequate imaging or surgical planning. 3) Underestimating the extent of soft tissue invasion, leading to local recurrence. 4) Not addressing pain adequately in the perioperative period. 5) Delaying chemotherapy due to surgical complications, which may allow metastasis to progress. 6) Overlooking the possibility of a second primary tumor in the contralateral limb.

Perioperative antimicrobial prophylaxis: Cefazolin 22 mg/kg IV at induction and every 90 minutes during surgery. Postoperative antibiotics are not routinely recommended unless infection is present. Analgesia: Preoperative: Morphine 0.5-1 mg/kg IM or IV, or Hydromorphone 0.05-0.1 mg/kg IV. Intraoperative: Fentanyl CRI at 5-10 mcg/kg/hr. Postoperative: Morphine 0.5-1 mg/kg IM or IV q4-6h, or Buprenorphine 0.01-0.02 mg/kg IV q6-8h. NSAIDs: Carprofen 2.2 mg/kg PO q12h for 3-5 days, or Meloxicam 0.1 mg/kg PO q24h. Local anesthesia: Epidural morphine 0.1 mg/kg or bupivacaine 1 mg/kg for hindlimb amputation. Chemotherapy: Carboplatin 300 mg/m² IV every 3 weeks for 4-6 cycles, or Cisplatin 70 mg/m² IV every 3 weeks (with saline diuresis), or Doxorubicin 30 mg/m² IV every 3 weeks. For cats: Carboplatin 200 mg/m² IV every 3 weeks. Supportive care: Maropitant 1 mg/kg IV q24h for nausea, and ondansetron 0.1 mg/kg IV q8h if needed. Bisphosphonates (e.g., pamidronate 1.3 mg/kg IV) may be used for pain palliation in non-surgical candidates.

Landmark studies have established the standard of care for osteosarcoma. A seminal study by Spodnick et al. (1992) reported a median survival time of 19 months in dogs with appendicular OSA treated with amputation and cisplatin chemotherapy, compared to 4 months with amputation alone. Another study by Berg et al. (1995) demonstrated that carboplatin is as effective as cisplatin with fewer side effects. The Veterinary Society of Surgical Oncology (VSSO) and ACVS have published consensus guidelines on the management of OSA, recommending amputation or limb-sparing followed by chemotherapy. A meta-analysis by Selmic et al. (2014) confirmed that adjuvant chemotherapy significantly improves survival. Recent studies have explored the role of immunotherapy and targeted therapies, but these remain experimental. Limb-sparing surgery has been evaluated in several studies, with complication rates of 30-50%, but functional outcomes are acceptable. The use of radiation therapy for palliation has been supported by studies showing improved pain control, but no survival benefit. Overall, the evidence supports aggressive surgical resection and chemotherapy as the best approach for improving survival and quality of life.